Dolutegravir (DTG) Based Fixed Dose Combination (FDC) of Tenofovir/Lamivudine/Dolutegravir (TLD) and Viral Load Suppression in Children in Port Harcourt, Nigeria

Main Article Content

Nsirimobu Ichendu Paul
Rosemary Ogochukwu Ugwu

Abstract

Background: Currently, dolutegravir (DTG) based fixed dose combinations (FDC) of tenofovir/ lamivudine/dolutegravir (TLD) and Abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) is now recommended by the World Health Organisation (WHO) as the preferred first-and second line antiretroviral drug necessitating transition of eligible children to TLD.

Objective: The objective of this study is to compare the HIV viral suppression rate at baseline and after 6 months of transition to TLD and to determine adverse drug reaction associated with the use of TLD if any.

Methods: This was a prospective cross-sectional study carried out among stable children who were on treatment and follow up for HIV disease at the Paediatric HIV clinic of the University of Port Harcourt Teaching Hospital (UPTH). All Children who were eligible for transition to TLD, whose care givers/parents gave a verbal consent and who gave consent or accent were recruited for the study. Information obtained included the sociodemographic characteristics, weight and height, ART regimen at initiation of treatment and when it was commenced, the baseline viral load and viral load 6 months after transition and any adverse drug reaction. Obtained data were analysed. Comparison of categorical variables was done using chi square and Fischer’s exact test while A p-value of < 0.05 was set as statistically significant.

Results: A total 106 children aged 9 to 18 years with a mean age of 13.4±2.3 years were recruited for the study. Sixty (56.6%) were males, while 59 (55.5%) were from the lower socioeconomic class. The mean weight was 44.4±11.1 kg while the mean height was 151.3 ± 15.2 cm. At baseline, 48 (45.3%) were virally suppressed (viral load < 1000 copies/ml), however after 6 months, 97 (91.5%) became virally suppressed, the difference in viral suppression rate was statistically significant (X2 =53.77, p= 0.0001).  Twenty-five (23.6%) had undetectable viral load (<20 copies/ml) at baseline while 61(57.5%) had undetectable viral load after transition. All those who were virally suppressed at baseline remained so 6 months after transition. Also, 80.6% (29/36) of those with treatment failure became virally suppressed. Only one child developed severe erythematous skin rashes. There was no statistically significant relationship between viral suppression and age, sex and social class (P >0.05).

Conclusion: This study has shown that DTG-based FDC is efficacious in the treatment of eligible children and adolescents with HIV/AIDS with significant viral load suppression in all age groups, gender and social class. Adverse drug reaction with the use of DTG-based ART is low. Transition to TLD is therefore advocated in eligible patients.

Keywords:
Dolutegravir (DTG), TLD, viral-load suppression, children.

Article Details

How to Cite
Paul, N. I., & Ugwu, R. O. (2020). Dolutegravir (DTG) Based Fixed Dose Combination (FDC) of Tenofovir/Lamivudine/Dolutegravir (TLD) and Viral Load Suppression in Children in Port Harcourt, Nigeria. Journal of Scientific Research and Reports, 26(2), 52-59. https://doi.org/10.9734/jsrr/2020/v26i230224
Section
Original Research Article

References

World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and prevention HIV infection. Recommendations for a public health approach- second edition; 2016.
Available:http://www.who.int/hiv/pub/arv/arv-2016/en/

World Health Organization. Policy brief: Transition to new anti retrovirals in HIV programmes; 2017.
Available:http://www.who.int/hiv/pub/toolkits/transition-to-new-arv/en/

World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV; 2018.
Available:http://apps.who.int/iris/bitstream/handle/10665/273632/WHO-CDS-HIV-18.18- eng.pdf?ua=1

Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807-1818.

Stellbrink H, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir in antiretroviral-naïve adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS. 2013;27:1771– 1778.

Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383(9936):2222-31.

Trottier B, Lake JE, Logue K, Brinson C, Santiago L, Brennan C, et al. Dolutegravir/abacavir/ lamivudine versus current ART in virally suppressed patients (STRIIVING): A 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther. 2017;22(4):295- 305.

Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest J, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: A systematic review and network meta-analysis. Lancet HIV. 2016;3:e510–20.

Imaz A, Martinez-Picado J, Niubo J, et al. HIV-1-RNA decay and dolutegravir concentrations in semen of patients starting a first antiretroviral regimen. J Infect Dis. 2016;214(10):1512-1519.

Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, et al. Antiviral activity, safety and pharmacokinetics/ pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25:1737–45.

Treviño A, Cabezas T, Lozano AB, García-Delgado R, Force L, Fernández-Montero JM, et al. Dolutegravir for the treatment of HIV-2 infection.J Clin Virol. 2015;64:12-5.

Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, et al. Safety, tolerability and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a Phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62:21–7.

Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018;32(6):729-737.

Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, et al. Psychiatric symptoms in patients receiving dolutegravir. J Acquir Immune Defic Syndr. 2017;74(4):423-431.

de Boer M van den Berk G, van Holten N, Oryszczyn J, Dorama W, Moha DA, Brinkman K. Intolerance of dolutegravir containing cART regimens in real life clinical practice. AIDS. 2016;30(18):2831-34.

Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Medicine. 2017;18(1):56-63.

Postel N, Mueller M, Wyen C, Brust J, Stoehr A, Glaunsinger T, et al. The DOL-ART cohort: Providing evidence from real-world data use of dolutegravir-based regimens in routine clinical care in Germany. Glasgow. Poster Abstract. 2016;133.

Hill AM, Mitchell N, Hughes S, Pozniak AL. Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: Meta-analysis of randomized trials. Curr Opin HIV AIDS. 2018;13(2):102-111.

Oyedeji GA. Socioeconomic and cultural background of hospitalized children in Ilesa. Nigerian Journal of Paediatrics. 1985;12:111-117.

Johnston V, Cohen K, Wiesner L, Morris L, Ledwaba J, Fielding KL, et al. Viral suppression following switch to second-line antiretroviral therapy: Associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch. The Journal of Infectious Diseases. 2013;209(5):711-720.